Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Bristol-Myers Squibb (BMY) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
DeucravacitinibSystemic Lupus Erythematosus, Psoriasis, Psoriatic Arthritis, Sjögren's DiseasePhase IIINot Yet RecruitingContinued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study CompletersAug 25, 2026
Bms-986446Healthy Participants, Alzheimer's DiseasePhase IRecruitingA Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose AdministrationAug 19, 2026
Navlimetostat, [14C]Navlimetostat, Bms-986504Healthy Female ParticipantsPhase INot Yet RecruitingA Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female ParticipantsAug 18, 2026
Bms-986511Major Depressive DisorderPhase IINot Yet RecruitingA Study to Evaluate BMS-986511 in Adults With Major Depressive DisorderAug 14, 2026
Golcadomide, Cc-99282, Bms-986369Kidney Failure, ChronicPhase IRecruitingA Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal FunctionAug 10, 2026
Carboplatin, Cisplatin, Pemetrexed, Osimertinib, Iza-Bren, Bms-986507Non-small Cell Lung CancerPhase IIIRecruitingStudy of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)Jun 26, 2026
Pumitamig, Pm8002, Imzokitug, Bnt327, Bms-986340Metastatic Non-Small Cell Lung Cancer (Nsclc), Locally Advanced Non-Small Cell Lung Cancer (Nsclc)Phase IIRecruitingA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Jun 26, 2026
Rosuvastatin, Dabigatran Etexilate, Famotidine, Bms-986533Healthy VolunteersPhase IRecruitingSingle and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy ParticipantsJun 01, 2026
Bms-986521Healthy VolunteersPhase IRecruitingA Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult ParticipantsMay 29, 2026
Zanzalintinib, Nivolumab, Cabozantinib, Enzalutamide, Atezolizumab, Prednisone, Abiraterone, Xl184, Xl092, CabometyxColorectal Cancer, Cancer, Prostate Cancer, Hepatocellular Carcinoma (Hcc), Renal Cell Carcinoma (Rcc), Non-Clear Cell Renal Cell Carcinoma (Nccrcc), Pancreatic Neuroendocrine Tumors (Pnet), Extra-Pancreatic Net (Epnet), Differentiated Thyroid Cancer (Dtc)Phase IIIEnrolling By InvitationLong-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyMay 27, 2026―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Bristol-Myers Squibb Company (CH:BMY) have in its pipeline
Bristol-Myers Squibb CH:BMY is currently developing the following drugs: Deucravacitinib, Bms-986446, Navlimetostat, [14C]Navlimetostat, Bms-986504, Bms-986511, Golcadomide, Cc-99282, Bms-986369, Carboplatin, Cisplatin, Pemetrexed, Osimertinib, Iza-Bren, Bms-986507, Pumitamig, Pm8002, Imzokitug, Bnt327, Bms-986340, Rosuvastatin, Dabigatran Etexilate, Famotidine, Bms-986533, Bms-986521, Zanzalintinib, Nivolumab, Cabozantinib, Enzalutamide, Atezolizumab, Prednisone, Abiraterone, Xl184, Xl092, Cabometyx, Navlimetostat, Bms-986504, Disp-10, Carboplatin, Gemcitabine, Paclitaxel, Nab-Paclitaxel, Pemetrexed, Pumitamig, Temozolomide, Bms-986504, Daraxonrasib, Nivolumab + Relatlimab Fdc, Bnt327, Mrtx1719, Navlimetostat, Nivolumab + Relatlimab, Bms-986213, Bms-986278, Admilparant, Moxifloxacin, Bms-986278, Bms-986528, Pembrolizumab, Pumitamig, Durvalumab, Pumitamig, Nivolumab, Bms-986525, Atezolizumab, Bevacizumab, Ipilimumab, Pumitamig, Nivolumab, Ipilimumab, Pumitamig, Cabozantinib, Karxt, Karxt, Karx-Ec, Temozolomide, Pumitamig, Bevacizumab, Bnt327, Pm8002, Bms-985521, Gemcitabine, Nab-Paclitaxel, Mfolfirinox, Pumitamig, Bms-986435, Myk-224, Admilparant, Rosuvastatin, Metformin, Bupropion, Omeprazole, Digoxin, Flurbiprofen, Repotrectinib, Gemcitabine, Cetuximab, Pembrolizumab, Nab-Paclitaxel, Bms-986523, Nivolumab, Folfox, Pumitamig, Capox, Bevacizumab, Folfiri, Folfox, Pumitamig, Capox, Xanomeline/Trospium Chloride, Karxt, Bms-986506, Bms-986454, Gemcitabine, Carboplatin, Eribulin, Pumitamig, Nab-Paclitaxel/Paclitaxel, Bms-986517. These drug candidates are in various stages of clinical development as the company works toward FDA approval.